Prior treatment with at least 1 systemic agent, with documented progressive disease after systemic agent(s), or documented adverse event(s) associated with prior systemic agent(s) that resulted in discontinuance of that (those) agent(s)
Not a candidate for curative treatments (e.g. resection, transplantation)
Child-Pugh A (score of 5-6)
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Adequate hematologic, hepatic and renal function
Ability to provide, for central review, a tumor tissue sample to determine the level of GPC-3 expression by IHC
Measurable disease by RECIST criteria
You may not be if
Child Pugh B or C
Known hepatocellular carcinoma with fibro-lamellar histology
Known brain or leptomeningeal metastases
Active infectious diseases requiring treatment except for hepatitis B and C
History of organ allograft including liver transplant
Anticipated or ongoing administration of anticancer therapies other than those administered in this study
Anticancer treatment within 2 weeks prior to entering the study
Patients who have not fully recovered from toxicities associated with previous HCC loco-regional or systemic therapies
Patients receiving interferon therapy
Pregnant or lactating women
Known HIV positivity or AIDS-related illness
History of significant hypersensitivity to similar agents (monoclonal antibody, protein-included drugs, Chinese hamster ovary products)
Clareo Health | A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
